Drug intelligence / Profile preview

Children's Mucinex

Development stage
Unknown
Lead developer
Reckitt
Modality
Small Molecules
Administration
Oral
01

Overview

Children's Mucinex is a line of over-the-counter (OTC) multi-symptom cold and cough medications specifically formulated for pediatric use, typically for children aged 4 years and older. Developed and manufactured by Reckitt Benckiser, the product line includes various formulations tailored to specific symptoms. Common active ingredients include guaifenesin, an expectorant that increases the volume and reduces the viscosity of secretions in the trachea and bronchi; dextromethorphan HBr, a cough suppressant that acts centrally on the cough reflex center; and phenylephrine HCl, a nasal decongestant that acts as an alpha-1 adrenergic receptor agonist to reduce swelling in the nasal passages. It is indicated for the temporary relief of symptoms associated with the common cold, such as chest congestion, cough, and nasal congestion.

Brand names
Children's MucinexChildren's Mucinex Cough & CongestionChildren's Mucinex Multi-Symptom ColdChildren's Mucinex Free & ClearChildren's Mucinex Chest CongestionChildren's Mucinex Stuffy Nose & Chest Congestion
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)

Beyond the preview

Go deeper on Children's Mucinex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Children's Mucinex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call